Mangalam Drugs and Organics Ltd

Stage 3 · Topping · week 1⚠ 2→3 today

As of 20 Nov 2026, Mangalam Drugs and Organics is in Stage 3, the topping phase, now in its first week (since 20 Nov 2026). It closed at ₹27.55, 55.8% below its 52-week high and below its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. More about the company

₹27.6
Close, 20 Nov 2026
-3.54% on the day
₹44 Cr · Micro cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

RS rank

Edge

—

MANGALAM's uptrend is tiring: in its first week into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.

Its relative strength is 4 of 99, below the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Is MANGALAM early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S4 23w
S2 18w
S4 20w
S4 25w
S4 22w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 23w → S1 3w → S2 6w → S3 5w → S4 5w → S1 2w → S2 18w → S3 11w → S4 20w → S1 12w → S4 25w → S1 5w → S4 22w → S1 8w → S2 3w → S3 1w current
Total tracked: 168 weeks across 16 stage runs.

MANGALAM among Pharmaceuticals110th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…110MANGALAMStage 3 · wk 14−9.4%
vs 52W High
-55.8%
₹23.8 lo₹62.3 hi
55.8% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 1
1w13w26w
Week 1, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-8.0%
200 DMA: ₹29.9 · sloping down
The stock has lost its 200-day average. In a topping stock that adds to the Stage 4 risk.
Rel Volume
0.86x
vs 50-day avg
Volume was close to average, nothing unusual. In Stage 3, volume spikes on down days are the warning to watch for.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-9.4%
3M
+2.3%
6M
-10.4%
YTD
+0.1%
1Y
-55.5%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Industry has 48 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Scan Membership
Not in any scan now.
Last appeared 2 Nov 2026
Recent Stage Timeline
2026-11-20S32→3
Wk 1 · Vol 0.86x
2026-11-19S2
Wk 3 · Vol 0.06x
2026-11-18S2
Wk 3 · Vol 0.29x
2026-11-17S2
Wk 3 · Vol 0.20x
2026-11-16S2
Wk 2 · Vol 0.41x
2026-11-13S2
Wk 2 · Vol 0.14x
2026-11-12S2
Wk 2 · Vol 0.21x
2026-11-11S2
Wk 2 · Vol 0.37x
2026-11-09S2
Wk 2 · Vol 0.37x
2026-11-06S2
Wk 1 · Vol 0.85x
2026-11-05S2
Wk 1 · Vol 0.55x
2026-11-04S2
Wk 1 · Vol 0.32x
Moving averages & range
50 DMA
₹30.6
200 DMA
₹29.9
52W High
₹62.3
52W Low
₹23.8
5D Low
₹27.6
Resistance levels (recent highs)
20d High
₹30.6
60d High
₹36.5
120d High
₹36.5
250d High
₹61.2
Next resistance
+11.2%
to 20d High
ROE
-35.2%
Profit margin -16.5%
Dividend Yield
0.00%
P/B 0.4

Mangalam Drugs and Organics: quick answers

What stage is Mangalam Drugs and Organics in?

As of 20 Nov 2026, Mangalam Drugs and Organics (MANGALAM) is in Stage 3, the topping phase. It entered Stage 3 on 20 Nov 2026 and is in its first week there. What the four stages mean

Is Mangalam Drugs and Organics in an uptrend?

Its uptrend has stalled. Mangalam Drugs and Organics is in Stage 3, the topping phase that follows an advance. It trades 8.0% below its 200-day average, which is falling.

How far is Mangalam Drugs and Organics from its 52-week high?

Mangalam Drugs and Organics closed at ₹27.55 on 20 Nov 2026, 55.8% below its 52-week high of ₹62.30. Its 52-week low is ₹23.78.

How has Mangalam Drugs and Organics performed over the past year?

As of 20 Nov 2026, Mangalam Drugs and Organics is down 55.5% over the past year and up 0.1% so far in 2026.

Which sector and industry is Mangalam Drugs and Organics in?

Mangalam Drugs and Organics is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. Additionally, it offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications. Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.